Clinical Trial Update: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BAY63-2521 in patients with interstitial lung disease–…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Pulmonary Hypertension

Drugs mentioned

• BAY63-2521

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Phase 2 | Status: COMPLETED